The FDA has rejected Sanofi's application seeking approval of tolebrutinib to treat certain forms of MS in its present form.

Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple sclerosis and is facing a delayed U.S. approval decision in another form of the ...

The vendor onboarding workflow begins with a Microsoft Form, where users submit their requests. These submissions are then routed through a structured approval process involving key stakeholders, such ...

Genentech, a member of the Roche Group, has won FDA approval for the first treatment indicated for both relapsing and primary progressive forms of multiple sclerosis (MS). Ocrevus™ (ocrelizumab) is a ...

ZURICH (Reuters) - Novartis said on Tuesday it would accelerate its bid to win approval for its experimental multiple sclerosis (MS) drug BAF312 and said it was now targeting patients at an earlier ...

Are you collecting data through Microsoft Forms and want to review and analyze the results in real time? Well, fortunately ...

Newly approved medications for secondary progressive MS can help slow disease progression or treat specific symptoms. Most people who are diagnosed with multiple sclerosis (MS) initially have ...